MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03822cam a2200337 a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GiCUC |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220222s2022 ua d f m 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-GiCUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GiCUC |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
Deposite |
| 097 ## - Thesis Degree |
|---|
| Thesis Level |
Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Classification number |
Cai01.08.09.Ph.D.2022.Ne.P |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Nesma Ahmed Abdelrahman Mohamed |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Possible modulatory effect of some antidiabetic drugs in lipopolysaccharide-induced neuroinflammation and cognitive impairment in mice / |
| Statement of responsibility, etc. |
Nesma Ahmed Abdelrahman Mohamed ; Supervised Nesrine Salaheldine Elsayed , Lamiaa Ahmed Ahmed , Ayman Elsayed Elsahar |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
الفاعلية المحتملة لبعض أدوية مرض السكر فى تعديل الالتهاب العصبى والاعتلال المعرفى المستحدثين بواسطة ليبوبولى سكاريد فى الفئران |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Cairo : |
| Name of publisher, distributor, etc. |
Nesma Ahmed AbdelRahman Mohamed , |
| Date of publication, distribution, etc. |
2022 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
132 P . : |
| Other physical details |
charts ; |
| Dimensions |
25cm |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Neuroinflammation plays a crucial role in the pathogenesis and progression of various neurodegenerative diseases such as Alzheimer{u2019}s disease (AD). A growing body of evidence supports that antidiabetic drugs such as metformin and dipeptidylpeptidase-4 inhibitors possess various neuroprotective effects that can improve learning and memory impairments in AD models. Thus, the present study aimed to investigate the possible neuroprotective effects of metformin and alogliptin each alone or in combination against intracerebroventricular (ICV) lipopolysaccharide (LPS)-induced neuroinflammation and cognitive impairment in mice as well as the potential mechanisms underlying these effects. Mice were treated with metformin (200 mg/kg/d; p.o.) and alogliptin (20 mg/kg/d; p.o.) alone or in combination for 14 days, starting 1 day prior to ICV LPS injection (8 og/oL in 3 oL). Both metformin and alogliptin alleviated LPSinduced cognitive impairment as assessed by Morris water maze and novel object recognition tests. Moreover, the treatment regimens reversed LPS-induced increases in toll-like receptor 4 (TLR4) and myeloid differentiation primary response protein 88 (MYD88) protein expression as well as nuclear factor-mB (NF-mB) p65 content. The tested regimens also abrogated the LPSinduced increase in microRNA-155 (miRNA-155) and decrease in suppressor of cytokine signaling-1 (SOCS-1) gene expression. Importantly, they rescued LPS-induced decrease in phosphorylated cyclic adenosine monophosphate response element binding protein (pCREB) protein expression in the brain. Consequently, the tested regimens ameliorated the measured inflammatory markers (tumor necrosis factor-Ü and interleukin-6 contents as well as ionized calcium-binding adaptor molecule-1 and glial fibrillary acid protein), amyloidogenic biomarkers (amyloid Ý (1-42) content and Ý-secretase activity) and apoptotic markers (Bax and Bcl-2). In conclusion, the present study sheds light on the potential neuroprotective effects of metformin and alogliptin alone or in combination against ICV LPS-induced neuroinflammation and its associated amyloidogenesis, apoptosis, and memory impairment via inhibition of TLR4/MyD88/NF-mB signaling, modulation of microRNA-155/SOCS-1 expression, and enhancement of pCREB expression in the brain |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Additional physical form available note |
Issued also as CD |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Metformin |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Alogliptin |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Cognitive impairment |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
lipopolysaccharide |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ayman Elsayed Elsahar , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Lamiaa Ahmed Ahmed , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Nesrine Salaheldine Elsayed , |
| Relator term |
|
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Amira |
| Reviser |
Cataloger |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Nazla |
| Reviser |
Revisor |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
